NCT02286219View on ClinicalTrials.gov

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 4, 2014

Primary Completion Date

June 8, 2017

Study Completion Date

June 8, 2017

Conditions
Solid Tumors That Overexpress HER2 (HER2 Positive)
Interventions
DRUG

FS102

Experimental

Trial Locations (6)

20007

MedStar Georgetown University Hospital, Washington D.C.

38120

The West Clinic, Memphis

90033

Anthony El-Khoueiry, Md, Los Angeles

98109

University of Washington, Seattle

78229-3900

Southwest Texas Addiction Research And Tech (Start) Center, San Antonio

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02286219 - Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab) | Biotech Hunter | Biotech Hunter